| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS44046321 | HTLV-1 | ENSG00000066468.24 | protein_coding | FGFR2 | Yes | No | 2263 | A0A141AXF1 D2CGD1 P21802 S4R381 |
| TVIS44046546 | HTLV-1 | ENSG00000066468.24 | protein_coding | FGFR2 | Yes | No | 2263 | A0A141AXF1 D2CGD1 P21802 S4R381 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | FGFR2 |
|---|---|
| DrugBank ID | DB08901 |
| Drug Name | Ponatinib |
| Target ID | BE0000748 |
| UniProt ID | P21802 |
| Regulation Type | inhibitor |
| PubMed IDs | 23468082 |
| Citations | Gozgit JM, Squillace RM, Wongchenko MJ, Miller D, Wardwell S, Mohemmad Q, Narasimhan NI, Wang F, Clackson T, Rivera VM: Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models. Cancer Chemother Pharmacol. 2013 May;71(5):1315-23. doi: 10.1007/s00280-013-2131-z. Epub 2013 Mar 7. |
| Groups | Approved; Investigational |
| Direct Classification | Benzanilides |
| SMILES | CN1CCN(CC2=CC=C(NC(=O)C3=CC(C#CC4=CN=C5C=CC=NN45)=C(C)C=C3)C=C2C(F)(F)F)CC1 |
| Pathways | Ponatinib Inhibition of BCR-ABL |
| PharmGKB | PA165980594 |
| ChEMBL | CHEMBL1171837 |
